Profile data is unavailable for this security.
About the company
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
- Revenue in USD (TTM)314.00k
- Net income in USD-237.73m
- Incorporated2010
- Employees96.00
- LocationViridian Therapeutics Inc221 CRESCENT STREET, BLDG. 17, SUITE 401WALTHAM 02453United StatesUSA
- Phone+1 (617) 272-4600
- Fax+1 (302) 655-5049
- Websitehttps://www.viridiantherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunome Inc | 14.02m | -106.81m | 893.62m | 55.00 | -- | 5.40 | -- | 63.75 | -3.33 | -3.33 | 0.7064 | 2.77 | 0.1625 | -- | -- | 254,872.70 | -123.77 | -94.54 | -148.94 | -112.66 | -- | -- | -761.92 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| OPKO Health Inc | 863.49m | -188.86m | 906.09m | 3.93k | -- | 0.7236 | -- | 1.05 | -0.2513 | -0.2513 | 1.15 | 1.80 | 0.4133 | 7.80 | 6.89 | 219,718.60 | -9.03 | -7.14 | -10.03 | -8.14 | 36.84 | 34.42 | -21.86 | -13.83 | 1.22 | -15.24 | 0.1574 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
| USANA Health Sciences, Inc. | 900.45m | 61.94m | 906.23m | 1.80k | 14.70 | 1.81 | 16.52 | 1.01 | 3.20 | 3.20 | 46.56 | 25.99 | 1.46 | 2.73 | -- | 500,250.00 | 10.03 | 16.23 | 12.49 | 21.75 | 80.98 | 81.42 | 6.88 | 8.96 | 3.20 | -- | 0.0026 | 0.00 | -7.77 | -4.98 | -8.02 | -12.76 | 4.86 | -- |
| Ocular Therapeutix Inc | 58.44m | -80.74m | 908.24m | 267.00 | -- | 7.41 | -- | 15.54 | -0.9939 | -0.9939 | 0.7233 | 0.7927 | 0.2912 | 2.47 | 2.46 | 218,883.90 | -40.23 | -46.70 | -48.19 | -54.18 | 90.96 | 89.36 | -138.15 | -228.65 | 6.59 | -6.57 | 0.4512 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| ARS Pharmaceuticals Inc | 30.00k | -54.37m | 916.62m | 24.00 | -- | 3.95 | -- | 30,554.03 | -0.5719 | -0.5719 | 0.0003 | 2.39 | 0.0001 | -- | -- | 1,250.00 | -21.13 | -20.37 | -21.45 | -21.32 | -- | -- | -181,216.70 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| BioCryst Pharmaceuticals Inc | 331.41m | -226.54m | 924.36m | 536.00 | -- | -- | -- | 2.79 | -1.18 | -1.18 | 1.72 | -2.21 | 0.6212 | 0.1658 | 6.16 | 618,306.00 | -42.46 | -47.95 | -55.84 | -64.89 | 98.59 | 97.06 | -68.36 | -114.94 | 3.12 | -1.11 | 2.19 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| Praxis Precision Medicines Inc | 2.45m | -123.28m | 926.56m | 82.00 | -- | 6.83 | -- | 378.65 | -23.64 | -23.64 | 0.3719 | 7.92 | 0.0241 | -- | -- | 29,841.46 | -121.41 | -74.04 | -161.17 | -85.12 | -- | -- | -5,037.88 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| Viridian Therapeutics Inc | 314.00k | -237.73m | 930.53m | 96.00 | -- | 3.34 | -- | 2,963.48 | -5.32 | -5.32 | 0.007 | 8.19 | 0.0007 | -- | 3.08 | 3,340.43 | -51.37 | -55.59 | -54.93 | -60.32 | -- | -- | -75,711.47 | -5,678.12 | -- | -- | 0.0437 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
| Relay Therapeutics Inc | 25.55m | -341.97m | 936.93m | 323.00 | -- | 1.20 | -- | 36.68 | -2.79 | -2.79 | 0.2095 | 5.90 | 0.0263 | -- | 9.79 | 79,089.78 | -35.19 | -28.55 | -36.97 | -29.54 | -- | -- | -1,338.66 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 937.41m | 284.00 | -- | -- | -- | 22.53 | -4.45 | -4.45 | 1.08 | -- | -- | -- | -- | 146,514.10 | -- | -29.45 | -- | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | -- | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| MacroGenics Inc | 58.75m | -9.06m | 952.17m | 339.00 | -- | 6.19 | 1,624.87 | 16.21 | -0.1525 | -0.1525 | 0.9462 | 2.46 | 0.203 | 6.15 | 1.76 | 173,300.90 | -3.13 | -37.76 | -3.82 | -45.53 | 86.00 | -- | -15.42 | -133.96 | 4.46 | -117.57 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| Cassava Sciences Inc | 0.00 | -97.22m | 954.00m | 29.00 | -- | 6.78 | -- | -- | -2.32 | -2.32 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -50.31 | -30.74 | -53.23 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Innoviva Inc | 310.46m | 179.72m | 960.91m | 112.00 | 6.85 | 1.44 | 4.46 | 3.10 | 2.24 | 2.24 | 3.96 | 10.66 | 0.2509 | 0.8825 | 4.19 | 2,771,991.00 | 14.52 | 26.24 | 15.62 | 28.53 | 86.27 | -- | 57.89 | 76.84 | 7.96 | -- | 0.398 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Tyra Biosciences Inc | 0.00 | -69.13m | 973.27m | 49.00 | -- | 3.90 | -- | -- | -1.62 | -1.62 | 0.00 | 4.75 | 0.00 | -- | -- | 0.00 | -28.10 | -- | -29.36 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -71.58m | 980.33m | 46.00 | -- | 3.53 | -- | -- | -2.18 | -2.18 | 0.00 | 5.95 | 0.00 | -- | -- | 0.00 | -40.31 | -42.26 | -44.80 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Liquidia Corp | 17.49m | -78.50m | 986.84m | 136.00 | -- | 18.84 | -- | 56.43 | -1.21 | -1.21 | 0.2691 | 0.6891 | 0.1413 | -- | 3.85 | 128,588.20 | -63.43 | -55.02 | -71.31 | -62.69 | 83.49 | 82.18 | -448.89 | -474.59 | -- | -26.14 | 0.4942 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
Data as of May 02 2024. Currency figures normalised to Viridian Therapeutics Inc's reporting currency: US Dollar USD
53.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 6.38m | 10.17% |
| Paradigm BioCapital Advisors LPas of 31 Dec 2023 | 4.79m | 7.64% |
| Perceptive Advisors LLCas of 18 Jan 2024 | 4.02m | 6.41% |
| Deep Track Capital LPas of 31 Dec 2023 | 3.63m | 5.79% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 3.13m | 4.98% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.90m | 4.62% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.71m | 4.32% |
| Maverick Capital Ltd.as of 31 Dec 2023 | 2.33m | 3.71% |
| AllianceBernstein LPas of 31 Dec 2023 | 2.06m | 3.28% |
| Commodore Capital LPas of 31 Dec 2023 | 1.92m | 3.07% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
